Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist
Harmony Biosciences宣布签订独家协议,开发和商业化Tpm-1116,一种高效的选择性口服Orexin-2受体激动剂
Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist
Harmony Biosciences宣布签订独家协议,开发和商业化Tpm-1116,一种高效的选择性口服Orexin-2受体激动剂
使用浏览器的分享功能,分享给你的好友吧